Latest Conference Articles

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

Dr Mohamed Abou Shousha discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.

Mark Wieland, MD, explores how Port Delivery System with ranibizumab provides drug delivery over an extended period.

In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Mark Wieland noted that the port delivery system with ranibizumab provides drug delivery over an extended period.

In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Mark Wieland, MD, noted that the Port Delivery System with ranibizumab provides drug delivery over an extended period.

Veeral Sheth, MD, presents research finding faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.

Ines Lains, MD, PhD, explores how mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

Dr Sunir J. Garg speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.

Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Ines Lains explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

Cathleen McCabe, MD, discusses VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, and how it provides opportunities for patients looking for spectacle independence.

Dr Cathleen McCabe describes how VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.

VUITY, the first and only approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

Nathan Hall, BS, MS, presents research on how epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.

Roger A. Goldberg, MD, MBA, notes how small misalignments in the plunger can lead to possible overdosing.

Ajay Kuriyan, MD, discusses fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting.

Dr Ajay Kuriyan discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular oedema in clinical trial setting."